Their findings indicated that deletion of PYGO2 led to enhanced CTL activation and tumor cell sensitivity to T cell-mediated killing, indicating that PYGO2 contributes to a microenvironment that suppresses immune responses through a p53/Sp1/Kit/Ido1 signaling network. Here, PYGO2 is linked to neoplasm.